Data / Drug companies / NorthStar RxLLC
NorthStar RxLLC: 383 products in the FDA NDC directory, labeler code 72603
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
NorthStar RxLLC (labeler code 72603) lists 383 products in the FDA National Drug Code Directory, covering 161 finished drugs by generic name. By type: 382 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 30, 2026.
The request: Watch NorthStar RxLLC (FDA labeler code 72603): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72603
- Products in commercial distribution
- 383
- Packages
- 539
- Finished drugs by generic name
- 161
- Prescription products
- 382
- Over the counter products
- 1
- Controlled substance products
- Schedule II 1, Schedule III 2, Schedule IV 6, Schedule V 9
- Flagged as original packager
- 355 of 355 products that carry the flag
- Started marketing in the last 12 months
- 86
- Products with a marketing end date set
- 8
- Earliest marketing start
- October 6, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 382 | 99.7% |
| Biologics (BLA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 382 | 99.7% |
| Over the counter drugs | 1 | 0.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 107 | 27.9% |
| Tablet, film coated | 67 | 17.5% |
| Injection, solution | 41 | 10.7% |
| Capsule | 38 | 9.9% |
| Solution | 16 | 4.2% |
| Injection | 15 | 3.9% |
| Injection, powder, for solution | 13 | 3.4% |
| Injection, powder, lyophilized, for solution | 8 | 2.1% |
| Capsule, extended release | 8 | 2.1% |
| Solution/ drops | 8 | 2.1% |
| Tablet, film coated, extended release | 7 | 1.8% |
| Tablet, delayed release | 7 | 1.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Norepinephrine Bitartrate | 72603-806 | Injection, solution, concentrate | Generic drugs (ANDA) | October 30, 2026 |
| Thiamine Hydrochloride | 72603-565 | Injection, solution | Generic drugs (ANDA) | October 14, 2026 |
| Famotidine | 72603-564 | Powder, for suspension | Generic drugs (ANDA) | October 1, 2026 |
| Colestipol hydrochloride | 72603-817 | Tablet, film coated | Generic drugs (ANDA) | September 1, 2026 |
| Ticagrelor | 72603-941 | Tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Ticagrelor | 72603-940 | Tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Olmesartan medoxomil | 72603-952 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Olmesartan medoxomil | 72603-951 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Olmesartan medoxomil | 72603-950 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Tadalafil | 72603-784 | Tablet, film coated | Generic drugs (ANDA) | August 3, 2026 |
| Tadalafil | 72603-783 | Tablet, film coated | Generic drugs (ANDA) | August 3, 2026 |
| Tadalafil | 72603-782 | Tablet, film coated | Generic drugs (ANDA) | August 3, 2026 |
| Tadalafil | 72603-781 | Tablet, film coated | Generic drugs (ANDA) | August 3, 2026 |
| Progesterone | 72603-975 | Capsule | Generic drugs (ANDA) | August 1, 2026 |
| Progesterone | 72603-974 | Capsule | Generic drugs (ANDA) | August 1, 2026 |
| Doxepin | 72603-920 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Doxepin | 72603-919 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Clozapine | 72603-914 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Clozapine | 72603-913 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Clozapine | 72603-912 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Clozapine | 72603-911 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Tranexamic acid | 72603-818 | Tablet | Generic drugs (ANDA) | August 1, 2026 |
| Sacubitril and Valsartan | 72603-882 | Tablet, film coated | Generic drugs (ANDA) | June 29, 2026 |
| Sacubitril and Valsartan | 72603-881 | Tablet, film coated | Generic drugs (ANDA) | June 29, 2026 |
| Sacubitril and Valsartan | 72603-880 | Tablet, film coated | Generic drugs (ANDA) | June 29, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.